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Disease activity (BDCAF)Abstract Background: Behc¸et disease (BD) is a multisystemic, chronic inﬂammatory disorder of
unknown etiology with diffuse clinical manifestations including the cardiovascular system.
Aim of the work: To assess left ventricular (LV) function and thoracic aorta elastic properties in
BD patients using Doppler echocardiography and to correlate echocardiographic ﬁndings with dis-
ease activity.
Patients and methods: The LV functions and thoracic aorta elastic properties were assessed in 30
BD patients and 30 controls using conventional and Tissue Doppler Imaging (TDI) echocardiogra-
phy. Disease activity was evaluated using Behc¸et’s disease current activity form (BDCAF).
Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), cholesterol and triglyceride levels
were measured.
Results: In BD patients, ESR and CRP were signiﬁcantly elevated while cholesterol and triglyc-
erides were comparable to the levels in the control. In conventional echocardiography, BD patients
had signiﬁcantly higher aortic diastolic diameter (p< 0.05), aortic stiffness index (p< 0.001), iso-
volumic relaxation time (p< 0.001), ﬂow propagation velocity (FPV) and peak E-wave
velocity/FPV (E/FPV) (p< 0.001) than the control group while aortic strain was signiﬁcantly lower
48 W.A. Hassan, H.H. Ebaidin BD patients (p< 0.05). Lateral mitral TDI echocardiography showed that myocardial perfor-
mance index was statically higher in BD patients (p< 0.001) while peak myocardial velocity and
myocardial acceleration during isovolumic contraction were signiﬁcantly lower (p< 0.001). The
BDCAF showed a signiﬁcant correlation with different echocardiographic parameters of systolic
and diastolic dysfunction.
Conclusions: Behc¸et disease patients have impaired LV systolic and diastolic functions and
altered aortic elastic properties that correlate with disease activity. TDI is more sensitive than con-
ventional echocardiography for the detection of early ventricular dysfunction in patients with BD.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Behc¸et disease (BD) is a generalized chronic inﬂammatory dis-
ease characterized by a triad of recurrent oral aphthous ulcers,
genital ulcers and uveitis but can involve many other systems
[1]. Several markers and mechanisms have been involved in
the pathogenesis of BD and development of vascuitis including
oxidative stress [2], apoptosis [3,4], cytokine and adipocytokine
overproduction [5–7], vascular endothelial growth factors [8,9]
and gene polymorphism [10]. Vasculitis and endothelial dys-
function are believed to be the pathogenic mechanism of a part
but not the whole of the clinical spectrum of the disease [11]. In
a study on Egyptian patients with BD, pulmonary artery
aneurysm one of the most serious aspects of the disease was
a leading cause of mortality [12].
Symptomatic cardiac disease is uncommon (1–6%) in BD
[13], but it was found in about 16.5% of a registry of Behc¸et
autopsy cases in Japan [14]. Cardiac involvement is more com-
mon in male patients and shows more arterial and venous
lesions when compared with those without cardiac manifesta-
tions [15]. Cardiac involvement includes intracardiac thrombo-
sis, pericardial involvement, myocardial and endocardial
complications and coronary artery disease [16]. Subclinical
coronary endothelial dysfunction was detected in 52% of
asymptomatic Egyptian BD patients in spite of a normal coro-
nary angiography [17]. In another study on Egyptian BD
patients, a morphologic evidence of subclinical carotid artery
atherosclerosis was veriﬁed and the disease activity signiﬁ-
cantly suggested cardiovascular involvement. [18].
Endocardial involvement may be limited to heart valves
including mitral and aortic valve prolapse, mitral or aortic
insufﬁciency, or involvement may include the endocardial sur-
face of cardiac chambers [19]. Endocardial involvement may
lead to endocardial ﬁbrosis involving the right or left ventricle
[20] and may predispose to intracavitary thrombus formation,
which may lead to pulmonary emboli [21]. Also, the inﬂamma-
tory process may involve arteries and arterioles of the coro-
nary system leading to silent ischemia, myocardial infarction
and systolic or diastolic dysfunction [22] which may be due
to ﬁlling abnormalities [23].
Ventricular diastolic function can be assessed by invasive
and non-invasive methods. Invasive measures for the assess-
ment of left ventricular (LV) diastolic function include the
peak instantaneous rate of LV pressure decline, the time con-
stant of LV relaxation, and the stiffness modulus. [24]
Although echocardiography does not directly measure these
parameters, it is the most practical non-invasive method for
evaluating LV diastolic function through measurement of LVvolumes and ejection fraction (LVEF) [25]. Also, measurement
of LV wall thicknesses (to identify presence and extent of LV
hypertrophy), left atrial (LA) volumes and pulmonary artery
(PA) pressures can help in the assessment of diastolic function
as patients with diastolic heart failure frequently have LV
hypertrophy, LA enlargement and increased PA pressures [26].
Tissue Doppler imaging (TDI) is the technique widely used
to detect subtle minimal impairment in myocardial function
and it enables measurement of high amplitude and low
frequency Doppler shifts caused by myocardial motion.
Segmental and global function can be measured and it is
minimally affected by preload in patients with impaired LV
relaxation [27,28].
This study aimed to assess LV function and thoracic aorta
elastic properties in patients with BD using conventional and
tissue Doppler echocardiography and to correlate echocardio-
graphic ﬁndings with disease activity.2. Patients and methods
2.1. Participants
Thirty patients, fulﬁlling the International Criteria for BD [29],
were recruited from the in-patients and out-patients’ clinic of
the Rheumatology and Rehabilitation Department of Benha
University Hospitals between April 2014 and February 2015.
Thirty age and sex matched apparently healthy individuals
with comparable body mass index (BMI) from the hospital
personnel, undergraduates; medical and nursing staffs were
also included as a control group. Patients older than 50, or
who have pre-existing overt heart diseases (e.g. ischemic heart
disease, conduction abnormalities, heart failure) or traditional
cardiovascular risk factors (e.g. hypertension, diabetes melli-
tus, hyperlipidemia, smoking, BMI > 35) were excluded.
Patients’ evaluation included full history taking with
recording of the disease duration, thorough physical examina-
tion, body mass index (BMI) assessment, Behc¸et’s disease
manifestations including vascular, cutaneous, oral and genital
ulceration. Fundus examination was undertaken by slit lamp
for the detection of ocular manifestations such as uveitis, reti-
nal vasculitis and optic neuritis and ongoing medications were
recorded. Disease activity using the Behc¸et’s Disease Current
Activity Form (BDCAF) [30] was assessed in all patients.
The local ethics committee of our institution (Benha
University, Faculty of Medicine) approved the study and all
participants gave a written informed consent before being
enrolled in this study.
Table 1 Clinical and laboratory characteristics, disease activ-
ity of the Behc¸et’s disease (BD) patients and controls.
Characteristics BD (n= 30) Control (n= 30) p
Male/female 19/11 18/12 >0.5
Disease duration (years) 4.3 ± 3.4 –
Oral ulcers 30 (100) –
Genital ulcers 19 (63.3) –
Eye involvement 12 (40) –
Vascular involvement 7 (23.3) –
Positive pathergy test 8 (26.7) –
Body mass index 27.9 ± 4.5 28.3 ± 5.2 >0.5
Heart rate (beat/min.) 77.2 ± 3.5 76.1 ± 5.2 >0.5
Systolic BP (mmHg) 120.7 ± 6.8 118.3 ± 5.5 >0.5
Diastolic BP (mmHg) 77.2 ± 4.5 76.7 ± 4.4 >0.5
ESR (mm/1sthr) 37.7 ± 16.8 12.7 ± 5.6 <0.5*
CRP (mg/l) 14.2 ± 11.08 4.3 ± 2.5 <0.5*
Cholesterol (mg/dl) 173.2 ± 26.7 185.3 ± 21.7 >0.5
HDL-cholesterol (mg/dl) 51.03 ± 10.5 48.2 ± 11.2 >0.5
LDL-cholesterol (mg/dl) 118.4 ± 13.9 120.4 ± 9.6 >0.5
Triglycerides (mg/dl) 139.2 ± 18.6 139.3 ± 10.4 >0.5
BDCAF 4.2 ± 3.2 –
ESR= Erythrocyte sedimentation rate, CRP = C reactive protein,
BDCAF= Behc¸et’s Disease Current Activity Form. Results are
presented as n (%) or mean ± SD.
* Signiﬁcant p< 0.05.
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Blood specimens were collected after an overnight fasting and
analyzed for complete blood count (CBC), erythrocyte sedi-
mentation rate (ESR) by Westergren’s method in mm/hour,
C-Reactive protein (CRP). Cholesterol, triglycerides, HDL-
cholesterol and LDL-cholesterol.
2.3. Echocardiographic examination
Echocardiography was done using a VIVID 7 EG cardiac ultra-
sound scanner, which included software for the acquisition of
both standard cardiac ultrasound and Doppler myocardial
imaging data using 2.5-MHz transducer. Standard echocardio-
graphy analysis was done using two-dimensional, m-mode, and
Doppler ﬂow measurements performed according to the
American society of echocardiography recommendations [31].
2.4. Conventional Echocardiography
- Measurements of left ventricle (LV) and thoracic aorta: The
following parameters were measured: LV end diastolic
diameter (LVEDD), LV end systolic diameter (LVESD),
fractional shortening (FS%), LV outﬂow diameter, left
atrial (LA) diameter, interventricular septal thickness, pos-
terior wall thickness in diastole, aortic systolic diameter (Ao
S), aortic diastolic diameter (Ao D), aortic strain (AS), aor-
tic stiffness index and aortic pressure strain modulus.
- Doppler measurements: The following parameters were
measured; mitral diastolic ﬂow, isovolumic relaxation time
(IVRT), velocity time integral (VTI) and stroke volume.
- Color M mode measurements: It was used to measure the
ﬂow propagation velocity (FPV) and to calculate the peak
E-wave velocity/FPV (E/FPV) (E/FPV) ratio; patients were
divided to those with a ratio <1.7 and those >1.7.
2.5. Tissue Doppler Imaging (TDI)
It was obtained in an apical four-chamber view; a 5 mm sam-
ple volume was placed just apical to the lateral mitral annulus.
Frame rate was adjusted between 120–180 frames/s and a cine-
loop of 3–5 consecutive heart beats was recorded. The follow-
ing were measured:
- Systolic indices that include peak myocardial velocity during
isovolumic contraction (IVV), myocardial acceleration during
isovolumic contraction (IVA), peak velocity during systolic
ejection (Sa), myocardial performance index (MPI) were calcu-
lated as the sum of isovolumetric contraction time and isovol-
umetric relaxation time divided by ejection time.
- Diastolic indices that include peak early (E) and late
myocardial diastolic velocity (A).
Statistical analysis: The collected data were analyzed using
SPSS version 16. Categorical data were presented as number
and percentages while continuous variables were presented as
mean and SD if parametric, and as median and range if non
parametric. Chi square, Z-test, Mann Whitney U test,
Kruskal–Wallis test and Spearman’s correlation coefﬁcientswere used as tests of signiﬁcance. Two sided p-value < 0.05
was considered signiﬁcant.
3. Results
Thirty BD patients (ages ranged from 18 to 49 years) with a
mean of 32.67 ± 9.55 years and thirty age and sex matched
apparently healthy control (ages ranged from 19 to 49 years)
with a mean of 33.2 ± 9.9 years were included in the study.
There was no signiﬁcant difference between both groups
regarding the mean of systolic BP, diastolic BP, BMI, choles-
terol and triglycerides (p> 0.05). Patients’ clinical and labora-
tory features are shown in (Table 1).
Regarding conventional echocardiography (Table 2); aortic
diastolic diameter, aortic stiffness index, isovolumic relaxation
time, FPV and E/FPV were signiﬁcantly higher (p< 0.05) in
BD patients compared to the control group while the aortic
strain was signiﬁcantly lower in BD patients compared to the
control group (p< 0.05). Other parameters (LVEDD,
LVESD posterior wall thickness, Septal thickness) showed
no signiﬁcant difference between patients and control.
Regarding TDI parameters (Table 3); myocardial perfor-
mance index (MPI) was statistically higher in BD patients
compared to the control group (p< 0.001) while peak
myocardial velocity (LV IVV) and acceleration (LVIVA) dur-
ing isovolumic contraction were signiﬁcantly lower
(p< 0.001). There was also a statistically signiﬁcant difference
among diastolic parameters: peak early (E wave) (p< 0.001)
and late (A wave) diastolic myocardial velocity being signiﬁ-
cantly lower in BD patients compared to the control group
(p< 0.05). Peak velocity during systolic ejection (Sa) showed
no statistically signiﬁcant difference between BD patients
and control (p> 0.05).
Table 2 Comparison between conventional echocardio-
graphic characteristics of the Behc¸et’s disease (BD) patients
and controls.
Echocardiographic parameter
Mean ± SD
BD (n= 30) Control
(n= 30)
p
LVEDD (mm/m2) 23.7 ± 1.5 23.1 ± 1.5 >0.05
LVESD (mm/m2) 15.02 ± 1.6 14.9 ± 0.8 >0.05
Septal thickness (mm/m2) 4.7 ± 0.3 4.8 ± 0.2 >0.05
Posterior wall thickness
(mm/m2)
4.7 ± 0.3 4.7 ± 0.4 >0.05
Left atrial diameter (mm/m2) 17.5 ± 1.2 17.5 ± 1.6 >0.05
Ao S (mm/m2) 14.8 ± 0.7 14.4 ± 0.9 >0.05
Ao D (mm/m2) 13.4 ± 0.6 12.6 ± 1.1 <0.05*
Aortic strain (%) 5.8 ± 2.98 8.2 ± 2.5 <0.05*
Aortic stiﬀness index 9.2 ± 4.98 4.9 ± 1.1 <0.001**
Stroke volume (ml) 57.1 ± 6.7 54.2 ± 5.5 >0.05
IVRT (ms) 89.8 ± 3.6 76.4 ± 5.4 <0.001**
VTI (cm) 17.98 ± 0.6 17.3 ± 1.4 >0.05
E/A ratio 1.1 ± 0.02 1.1 ± 0.03 >0.05
FPV (cm/s) 45.4 ± 4.6 65.3 ± 5.99 <0.001**
E/FPV 1.6 ± 0.2 1.1 ± 0.1 <0.001**
LV = left ventricular, EDD= end diastolic volume, ESD= end
systolic volume, AoS = aortic systolic diameter, Ao D= aortic
diastolic diameter, IVRT= isovolumic relaxation time,
VTI = velocity time integral, E/A = peak early/late myocardial
velocity ratio, FPV= ﬂow propagation velocity.
* Signiﬁcant p< 0.05.
** Highly signiﬁcant p< 0.001.
Table 3 Comparison between Tissue Doppler Imaging char-
acteristics of the Behc¸et’s disease (BD) patients and controls.
TDI parameter
Mean ± SD
BD (n= 30) Control
(n= 30)
p
LV Sa (m/s) 0.12 ± 0.006 0.12 ± 0.01 >0.5
LV IVV (m/s) 0.11 ± 0.016 0.13 ± 0.006 <0.001**
LV IVA (m/s2) 2.28 ± 0.35 3.60 ± 0.11 <0.001**
LV MPI 0.42 ± 0.007 0.28 ± 0.02 <0.001**
E (cm/s) 0.12 ± 0.009 0.14 ± 0.01 <0.001**
A (cm/s) 0.11 ± 0.02 0.12 ± 0.007 <0.05*
TDI: Tissue Doppler Imaging, LV = left ventricular, Sa = peak
velocity during systolic ejection, IVV = peak myocardial velocity
during isovolumic contraction, IVA=myocardial acceleration
during isovolumic contraction, MPI = myocardial performance
index. E = peak early diastolic myocardial velocity, A = peak late
diastolic myocardial velocity.
* Signiﬁcant p< 0.05.
** Highly signiﬁcant p< 0.001.
Table 4 Correlations between Behc¸et’s Disease Current
Activity Form (BDCAF) and different conventional and tissue
Doppler echocardiography variables in Behc¸et’s disease (BD)
patients.
Echocardiographic parameters BDCAF
r p
LVEDD (mm/m2) 0.12 >0.5
LVESD (mm/m2) 0.16 >0.5
Septal thickness (mm/m2) 0.13 >0.5
Posterior wall thickness (mm/m2) 0.21 >0.5
Aortic strain (%) 0.52 <0.5*
Aortic stiﬀness index 0.71 <0.001**
IVRT (ms) 0.54 <0.5*
VTI (cm) 0.14 >0.5
E/A 0.12 >0.5
FPV (cm/s) 0.58 <0.5*
E/EPV 0.53 <0.5*
LV TDI Sa (m/s) 0.18 >0.5
LV IVV (m/s) 0.47 <0.5*
LV IVA (m/s2) 0.51 <0.5*
LV MPI 0.57 <0.5*
E wave (cm/s) 0.48 <0.5*
A wave (cm/s) 0.27 >0.5
LV= left ventricular, EDD= end diastolic volume, ESD= end
systolic volume, Ao S = aortic systolic diameter, Ao D= aortic
diastolic diameter, IVRT= isovolumic relaxation time,
VTI = velocity time integral, E/A = peak early/late myocardial
velocity ratio, FPV = ﬂow propagation velocity, Sa = peak
velocity during systolic ejection, IVV= peak myocardial velocity
during isovolumic contraction, IVA=myocardial acceleration
during isovolumic contraction, MPI = myocardial performance
index. E = peak early diastolic myocardial velocity, A = peak late
diastolic myocardial velocity.
* Signiﬁcant p< 0.05.
** Highly signiﬁcant p< 0.001.
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p< 0.05), E/FPV (r= 0.53, p< 0.05) and the aortic stiffness
index (r= 0.71, p< 0.001) and a signiﬁcant negative correla-
tion with LVMPI (r= 0.57, p< 0.05), aortic strain
(r= 0.52, p< 0.05), FPV (r= 0.58, p< 0.05) LVIVA
(r= 0.51, p< 0.05), LVIVV (r= 0.47, p< 0.05) and E
wave (r= 0.48, p< 0.05) (Table 4).
4. Discussion
Behc¸et disease (BD) may affect many systems and the underly-
ing pathological mechanism is believed to be due to involvementof the arteries and arterioles with narrowing of their lumen by
focal ﬁbrinoid deposition and ﬁbroelastic proliferation. [32].
Cardiac involvement in BD can be seen frequently without
symptoms [33] and silent myocardial ischemia that is deﬁned
as objective documentation of myocardial ischemia in the
absence of angina or ischemic equivalents has also been
reported in patients with BD [34].
In the present study, it was shown that left ventricle dias-
tolic functions were impaired in BD patients as measured by
conventional echocardiography and TDI in the form of pro-
longed isovolumic relaxation time (IVRT) (p< 0.001), low
ﬂow propagation velocity(FPV) (p< 0.001), prolonged [E
(p< 0.001) and A waves (p< 0.05)]. Our results conﬁrmed
the results of others who found impairment of LV diastolic
functions in BD patients compared to the controls [35–37].
This can be explained as vasculitis affecting the intramural
and small coronary arteries which may cause weakening of
endocardial and myocardial tissue and replacement by ﬁbrosis
due to myocardial ischemia [38].
Gu¨llu¨ et al. [39] reported a high prevalence of silent
myocardial ischemia (25%) and Tu¨rko¨lmez et al. [40] recom-
mended myocardial perfusion scintigraphy in patients with
long lasting BD for screening of silent myocardial ischemia.
Also, we found altered aortic elastic properties in the form
of decreased aortic strain and increased aortic stiffness index
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dysfunction in BD patients. Our results conﬁrmed the results
of others which found increased aortic stiffness in BD patients
[38,41,42]. This increase in arterial stiffness in BD patients may
be related to endothelial dysfunction and the inﬂammatory
process associated with BD [43] leading to smooth muscle cell
proliferation and increased synthesis of structural proteins
including collagen [45]. In contrast to our results, in the study
of Ku¨ru¨m et al. [44] they found no difference in arterial stiff-
ness between BD and control and they attribute this to the
small sample size and short disease duration.
Tissue Doppler imaging (TDI) allows quantitative measure-
ments of myocardial contraction and relaxation velocities of a
selected myocardial segment and early detection of subclinical
global and regional myocardial dysfunctions [28]. In our study
TDI detected early left ventricular systolic dysfunction that
was not evident by conventional echocardiography in the form
of decreased peak myocardial velocity (IVV) and acceleration
(IVA) during isovolumic contraction and increased myocardial
performance index (MPI) (p< 0.001). Yagmur et al. [37] sug-
gested that impaired systolic function before the development
of overt cardiac failuremay be due to early affection of subendo-
cardial longitudinal ﬁbers with no distortion in circumferential
function in BDdue to the deterioration in coronarymicrovascu-
lar function, which is attributed to small vessel vasculitis.
We found a signiﬁcant correlation between BDCAF and
aortic stiffness parameters; aortic strain (r= 0.52,
p< 0.05), aortic stiffness index (r= 0.68, p< 0.05) and also
with the systolic and diastolic dysfunction parameters. Caldas
et al. [42] found increased arterial stiffness in BD with systemic
disease more than in mucocutaneous BD patients. This can be
related to the inﬂammatory process that causes atherosclerosis
through altered lipid peroxidation [45] and increased levels of
intracellular adhesion molecules. Also, Ikonomidis et al. [38]
found BD with vascular complication to have more myocardial
and aortic wall dysfunction and attributed this to a common
pathophysiologic pathway that may elevate inﬂammatory
cytokines as interleukin-2 (IL-2) and IL-6.
In conclusion, BD patients have impaired left ventricular
systolic and diastolic functions and altered aortic elastic prop-
erties that correlate with disease activity. Tissue Doppler
Imaging is more sensitive than conventional echocardiography
for the detection of early ventricular dysfunction in patients
with BD.
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